SlidePresenter
company on 1 show · 13 statements across 1 episodes · said 22 times in 1 episodes since 2019
Mentions by year, every show
tap a year for its mentions
Top Founders 22
2019 22 mentions in 1 episode
every mention on every show, scene by scene, with the transcript →
13 statements about SlidePresenter, every show
Walker: Taking a Co-Founder Early Could Have Prevented SlidePresenter's Pivot
“I'm a single founder. I would probably take someone else to the team at the beginning, first of all. Second I would probably be more hypothesis-driven at the beginning when I found a company so I could avoid this pivot maybe at the beginning.”
Walker: SlidePresenter targets roughly a one-year CAC payback period
“We would spend that whole amount to acquire them, but we have a very much higher lifetime value. So it's, yeah, it's roughly one year.”
Walker: SlidePresenter generates annual recurring revenue in the seven figures
“We're seven digits. We're not eight digits yet. And we're not in the highest eight seven digits area.”
Walker: SlidePresenter serves around 100 large enterprise corporate clients
“And now we have around a hundred corporations, like large corporations and some minor small customers.”
Walker: SlidePresenter currently employs a total of 28 people
“The overall team size today is 28 people.”
Walker: SlidePresenter grew revenue by 60% over the trailing 12 months
“So the overall revenue growth from then to today, like one year, Or 60% for the 12 months.”
Walker: SlidePresenter has negative revenue churn and ~1.5% monthly gross churn
“Looking at our churn rates we have a negative revenue churn but if you only look at the churn it's like a, like, 1.5 percent .”
Walker: SlidePresenter sees roughly 50% average year-over-year account expansion
“The broader base, it's like, it could be around as an average, maybe something like 50%.”
Walker: SlidePresenter focuses on 1,000+ employee enterprises in pharma and finance
“Like we have customers that are all large successful corporations with more than 1000 employees. So that's our current focus target group from across all industries, mostly from pharmaceutical endurance and financial industries.”